Although the fundamental concepts of pharmacokinetics remain the same, ocular pharmacokinetics has its own challenges due to the uniqueness of barrier properties posed by various ocular tissues and its growing complexity with different routes of ocular administration. A thorough understanding of the barrier nature will aid in tailoring a drug or its carrier's physicochemical properties to its advantage. In order to deliver the right payload of a drug at the target site, various approaches can be taken to leverage the pharmacokinetics that includes molecular design based on desirable physicochemical properties, formulation approaches, and alternative routes of administration. In this chapter, a brief overview of the barrier properties with respect to various routes of administration is presented along with the physicochemical properties that influence the pharmacokinetics of ocular drugs. Recent advances in ocular pharmacokinetics are discussed in addition to new perspectives in interpreting existing data.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/164_2016_32 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nanoemulsion-based pseudopolyrotaxane hydrogel for enhanced corneal bioavailability and treatment of corneal inflammation.
J Control Release
January 2025
School of Pharmacy, Nantong University, Nantong, Jiangsu Province 226001, China. Electronic address:
Corneal inflammation, a condition that can potentially lead to blindness, is often treated with topical eye drops. However, the limited ocular drug bioavailability of the eye drops necessitates frequent dosing. Herein, a nanoemulsion-based pseudopolyrotaxane hydrogel was fabricated to improve corneal bioavailability and thereby suppress inflammation.
View Article and Find Full Text PDFA water-soluble drug nanoparticle-loaded in situ gel for enhanced precorneal retention and its transduction mechanism of pharmacodynamic effects.
Int J Pharm
December 2024
Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address:
Article Synopsis
- Timolol maleate (TM) is commonly used to treat glaucoma, but traditional eye drops don't work well due to the eye's barriers.
- Researchers created a new formulation using nanoparticles (NPs) and an in situ gel (ISG) system to improve drug delivery and retention.
- The new formulation showed excellent safety, longer duration in the eye, and effectively lowered intraocular pressure for up to 12 hours, providing insights for future glaucoma treatments.
Sustained Release of RNA Nanoparticles from Reservoir Implant for Ocular Delivery.
J Pharm Sci
December 2024
Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267. Electronic address:
Article Synopsis
- RNA nanoparticles show promise for ocular delivery, particularly for chronic eye diseases, using a periocular reservoir implant like an episcleral implant.
- The study aimed to create these implants, test their release performance with model substances and RNA nanoparticles, and apply hindered transport theory to analyze the release rates.
- Findings showed that the release rates depended on both the size of the substances and the implant membrane's characteristics, indicating a potential for extended delivery of RNA nanoparticles through this implantation method.
Suprachoroidal delivery of viral and non-viral vectors for treatment of retinal and choroidal vascular diseases.
Am J Ophthalmol
December 2024
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University, Baltimore, MD; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD; Departments of Chemical & Biomolecular Engineering and Materials Science & Engineering, Johns Hopkins University, Baltimore, MD; Departments of Neurosurgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD; Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD. Electronic address:
Current treatments for retinal and choroidal neovascular diseases suffer from insufficient durability, including anti-vascular endothelial growth factor-A (VEGF-A) agents. It is, therefore, of interest to explore alternative methods that could allow for robust improvement in visual acuity with fewer injections required. Amongst various pre-clinical and clinical studies in the literature, a promising approach is the use of suprachoroidal injection with viral and non-viral gene delivery vectors.
View Article and Find Full Text PDFPharmacokinetics and metabolism of ketoconazole after single ocular instillation in Sprague-Dawley rats.
ADMET DMPK
November 2024
Bioduro-Sundia, Shanghai, China.
Background And Purpose: Ketoconazole is limited to its conditioned oral use due to hepatic toxicity. Its ocular eye drop administration may be an option for mycotic keratitis treatment. Therefore, it is necessary to explore its pharmacokinetic and metabolic profile via topical ocular administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!